– USA, UT – Xenter, Inc., the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of Jim Tobin to its Board of Directors.
“We are thrilled to welcome Jim Tobin to our Board of Directors,” said Richard Linder. “Jim is one of the most experienced executives in the life science industry. We look forward to Jim’s help in guiding Xenter as we develop and market new wireless medical device technologies, develop novel therapeutic drugs, and launch a new global health data platform.”
Founded in 2020 by seasoned life sciences entrepreneur Richard J. Linder, Xenter is innovating new wireless technologies and techniques for interventional cardiology, interventional radiology, and neuro-interventional radiology. Additionally, Xenter is launching a digital health platform that will leverage new wireless interventional devices that provide physiologic data and images simultaneously and enable patients to have access and control of their medical data.
Before joining Xenter, Tobin served as President and CEO of Boston Scientific from March 1999 to July 2009, during which time the company’s revenues grew from more than $2 billion to more than $8 billion. During this period, Tobin led Boston Scientific in the achievement of milestones including the successful launch of multiple products, significant acquisitions and strategic alliances (such as the transformative purchase of Guidant Corporation), and the growth of the company’s international business to more than 40% of annual revenues.
Before this role, Tobin served as President and CEO of Biogen Inc., where he was instrumental in making it one of the world’s most successful biotechnology companies. Before Biogen, Tobin was an executive with Baxter International, where he became President and Chief Operating Officer in 1992 and was responsible for all operations of the $9 billion company.
“I am delighted to join the Board of Directors. Xenter is developing technology that has the potential to advance interventional medicine by 30 years, improving patient outcomes and generating unprecedented amounts of qualitative data that can guide the development of new devices and therapeutic drugs,” said Jim Tobin.
He added: “I look forward to working with the other directors and the management team at Xenter as the company moves forward with these exciting initiatives.”
Tobin holds an MBA from Harvard Business School and a bachelor’s degree in business from Harvard College.
About Xenter
Xenter, Inc. is a privately held company headquartered in Salt Lake City, Utah, that is focused on developing new wireless medical device technologies, innovative digital health tools that will enable individual patients to own and manage their health information, and novel therapeutic drugs utilizing Physical Intelligence and patient-supplied data. Xenter has assembled a team of medical scientists, chemical engineers, medical device engineers, researchers, data scientists, and some of the world’s most accomplished entrepreneurs and industry veterans to solve some of the largest challenges in healthcare, medicine, and engineering.
The Xenter platform will enable novel therapeutic drug research by combining Physical Intelligence data with historical health data and other relevant information provided by patients and other patient-authorized sources.
Xenter is assembling an all-star cast of medical scientists, cellular biologists, pharmacologists, electrical engineers, mechanical engineers, researchers, practitioners, and some of the world’s most experienced and accomplished entrepreneurs and industry veterans. The appointment of Jim Tobin is the first of multiple significant appointments Xenter will announce within the coming several weeks.
Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity, and invasiveness of cardiac procedures.
For more information: https://xentermd.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
